[1]孙雅楠,王先令,谷伟军,等.3例胰腺神经内分泌肿瘤致异位ACTH综合征临床分析并文献复习[J].国际内分泌代谢杂志,2024,44(01):59-62.[doi:10.3760/cma.j.cn121383-20221107-11018]
　Sun Yanan,Wang Xianling,Gu Weijun,et al.Analysis of three patients with ectopic ACTH syndrome caused by pancreatic neuroendocrine tumors and literature review[J].International Journal of Endocrinology and Metabolism,2024,44(01):59-62.[doi:10.3760/cma.j.cn121383-20221107-11018]

点击复制

3例胰腺神经内分泌肿瘤致异位ACTH综合征临床分析并文献复习()

分享到：

参考文献/References:

[1] Öberg K.Management of functional neuroendocrine tumors of the pancreas[J].Gland Surg,2018,7(1):20-27.DOI:10.21037/gs.2017.10.08.
[2] 李浩明,曲玉清,王先令,等.286例功能性胰腺神经内分泌肿瘤的临床特点及治疗:一项单中心回顾性研究[J].国际内分泌代谢杂志,2021,41(3):178-183.DOI:10.3760/cma.j.cn121383-20200729-07073.
[3] Ferriere A,Tabarin A.Biochemical testing to differentiate Cushing's disease from ectopic ACTH syndrome[J].Pituitary,2022,25(5):705-708.DOI:10.1007/s11102-022-01241-z.
[4] Araki T,Liu NA,Tone Y,et al.E2F1-mediated human POMC expression in ectopic Cushing's syndrome[J].Endocr Relat Cancer,2016,23(11):857-870.DOI:10.1530/ERC-16-0206.
[5] Nomura C,Nakano Y,Tanaka T,et al.Somatostatin receptor-negative and fluorodeoxy glucose-positron emission tomography-positive lung neuroendocrine tumor G1 exhibiting cyclic Cushing's syndrome[J].Intern Med,2022,61(24):3693-3698.DOI:10.2169/internalmedicine.9238-21.
[6] Kanzaki T,Takahashi Y,Higuchi T,et al.Evaluation of a correction method for ¹¹¹In-pentetreotide SPECT imaging of astroenteropancreatic neuroendocrine tumors[J].J Nucl Med Technol,2020,48(4):326-330.DOI:10.2967/jnmt.120.249680.
[7] Wang H,Ba Y,Xing Q,et al.Differential diagnostic value of bilateral inferior petrosal sinus sampling(BIPSS)in ACTH-dependent Cushing's syndrome:a systematic review and Meta-analysis[J].BMC Endocr Disord,2020,20(1):143.DOI:10.1186/s12902-020-00623-3.
[8] Strosberg JR,Halfdanarson TR,Bellizzi AM,et al.The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors[J].Pancreas,2017,46(6):707-714.DOI:10.1097/MPA.0000000000000850.
[9] Ma ZY,Gong YF,Zhuang HK,et al.Pancreatic neuroendocrine tumors:a review of serum biomarkers,staging,and management[J].World J Gastroenterol,2020,26(19):2305-2322.DOI:10.3748/wjg.v26.i19.2305.
[10] Börzsei R,Zsidó BZ,Bálint M,et al.Exploration of somatostatin binding mechanism to somatostatin receptor subtype 4[J].Int J Mol Sci,2022,23(13):6878.DOI:10.3390/ijms23136878.
[11] 包旭东,卢琳,潘慧,等.功能性胰腺神经内分泌肿瘤的药物治疗进展[J].临床药物治疗杂志,2019,17(11):18-23.DOI:10.3969/j.issn.1672-3384.2019.11.005.
[12] Pivonello R,De Leo M,Cozzolino A,et al.The treatment of Cushing's disease[J].Endocr Rev,2015,36(4):385-486.DOI:10.1210/er.2013-1048.
[13] Tritos NA,Biller BM.Medical management of Cushing's disease[J].J Neurooncol.2014,117(3):407-414.DOI:10.1007/s11060-013-1269-1.
[14] Zhang C,Jin J,Xie J,et al.The clinical features and molecular mechanisms of ACTH-secreting pancreatic neuroendocrine tumors[J].J Clin Endocrinol Metab,2020,105(11):dgaa507.DOI:10.1210/clinem/dgaa507.
[15] Genc CG,Klümpen HJ,van Oijen MGH,et al.A nationwide population-based study on the survival of patients with pancreatic neuroendocrine tumors in the Netherlands[J].World J Surg,2018,42(2):490-497.DOI:10.1007/s00268-017-4278-y.